Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence

1
Differentiating Among Incretin Agents for Type 2
Diabetes Weighing the Evidence
2
(No Transcript)
3
Program Goals
4
Insulin Deficiency and Glucagon Hypersecretion in
T2D
5
Postprandial Glucagon Is Excessive and Not
Corrected by Exogenous Insulin
6
Incretin Hormome Physiology
7
Signal Transduction and GLP-1
8
(No Transcript)
9
(No Transcript)
10
Summary of Main GLP-1 Effects
11
(No Transcript)
12
2012 ADA/EASD Position Statement
13
Impact of Exenatide Twice-Daily Therapy Over 3
Years Effect on HbA1c and Body Weight
14
(No Transcript)
15
(No Transcript)
16
Considerations in Choosing a GLP-1 Receptor
Agonist
17
EXN Once Weekly vs Sitagliptin and Pioglitazone
HbA1c Reduction
18
(No Transcript)
19
Nausea With GLP-1 Receptor Agonists Tends to
Decrease With Time
20
Strategies to Minimize the Occurrence of Nausea
21
Minor Hypoglycemia With GLP-1 Receptor Agonists
22
Liraglutide/Exenatide Black Box WarningRisk of
Thyroid C-Cell Tumors
23
Incretin-based TherapiesConcern About Acute
Pancreatitis
24
Sitagliptin and Exenatide Associated With
Increased Risk for Hospitalization for Acute
Pancreatitis
25
Incretin-based Therapies Renal Impairment
26
Incretin-based Therapies Associated With
Increased Alpha-Cell Hyperplasia
27
Exenatide Twice Daily Added to Insulin Glargine
28
Closing Comments
29
Abbreviations
30
Abbreviations (cont)
31
Abbreviations (cont)
32
References
33
References (cont)
34
References (cont)
35
References (cont)
36
References (cont)
37
References (cont)